The PI3K/Akt/mTOR signaling pathway after EGFR activation is one of the most significant signaling pathways in cancer cells, and as clinical research has revealed, mutations in both EGFR and PTEN would lead to continuous activation of the signaling pathway, thus contributing to tumorigenesis and resistance to therapy [50]. This evidence concerns the gene PIK3CA and cancer.